fulvestrant has been researched along with Prostatic Neoplasms in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 13 (46.43) | 29.6817 |
| 2010's | 14 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Razik, AF; Alexi, X; Alexis, MN; Ioannou, E; Roussis, V; Vagias, C | 1 |
| Bearss, NR; Bhatnagar, D; Boue, SM; Burow, ME; Cleveland, TE; Erhardt, PW; Khupse, RS; Reese, MD; Sarver, JG; Trendel, JA; Wiese, TE | 1 |
| Dalmau, E; Fernández-Morales, LA; Marín, M; Martinez Vila, C; Oliveres, H; Pardo, JC; Ribera, P; Segui, MA | 1 |
| Campbell, DC; Johnston, R; McDade, SS; Nugent, S; Panov, KI; Ray, S; Waugh, D | 1 |
| Helgason, CD; Mager, DL; Nakamura, H; Romanish, MT; Wang, Y; Xue, H | 1 |
| Crippa, V; Messi, E; Piccolella, M; Poletti, A; Tetel, MJ | 1 |
| Chan, QK; Ho, SM; Lau, KM; Leung, YK; Ma, FM; Maranchie, J; Ng, CF; To, KF; Tse, HM | 1 |
| Casa, AJ; Cui, X; Dearth, RK; Lee, AV; Litzenburger, BC | 1 |
| Barbosa-Desongles, A; Barquinero, J; Bellmunt, J; de Torres, I; Hurtado, A; López-Avilés, S; Morote, J; Munell, F; Petriz, J; Pinós, T; Reventós, J; Santamaria-Martínez, A | 1 |
| Ashraf, U; Chadha, MK; Escott, P; Lawrence, D; Levine, E; Payne, V; Silliman, C; Tian, L; Trump, DL | 1 |
| Alberola Candel, V; Gasent Blesa, JM; Giner Marco, V; Giner-Bosch, V; Laforga Canales, JB; Provencio Pulla, M | 1 |
| Droz, JP; Féchon, A | 1 |
| Blesa, JM; Candel, VA | 1 |
| Corey, E; Hess, D; Kalhorn, T; Montgomery, B; Nelson, PS; Vessella, R | 1 |
| Freudenberg, JM; Fullenkamp, AN; Ho, SM; Medvedovic, M; Szeto, CY; Tam, NN | 1 |
| Gupta, G; Jain, A; Jain, RK; Kumar, R; Maikhuri, JP; Verma, V | 1 |
| Du, X; Mayer, D; Miao, L; Shi, J; Wang, CY; Yu, L; Zhang, J | 1 |
| Akaogi, K; Fujimura, T; Fukamizu, A; Homma, Y; Inoue, S; Ishida, J; Kako, K; Kimura, K; Murayama, A; Nakajima, Y; Ogawa, S; Osakabe, A; Sunahara, N; Suzuki, T; Yamaguchi, C; Yanagisawa, J | 1 |
| Cross, HS; Farhan, H; Wähälä, K | 1 |
| Andò, S; Briand, PA; Carpino, A; Fasanella, G; Maggiolini, M; Pezzi, V; Picard, D; Rago, V; Recchia, AG; Vivacqua, A | 1 |
| Mariani, SM | 1 |
| Cheng, JS; Ezaki, K; Kawashima, H; Kurisu, T; Nakatani, T; Sugita, S; Tanaka, T | 1 |
| Gao, Y; Ho, SM; Lau, KM; Leung, YK; Zhang, X | 1 |
| Bhattacharyya, RS; Feldman, D; Krishnan, AV; Swami, S | 1 |
| Auricchio, F; Bottero, D; Castoria, G; Ciociola, A; De Falco, A; De Stasio, R; Di Domenico, M; Lombardi, M; Migliaccio, A; Nanayakkara, M; Varricchio, L | 1 |
| Allen, JD; Arnold, JT; Blackman, MR; Le, H; Liu, X; McFann, KK | 1 |
| Carruba, G; Castagnetta, LA; Comito, L; D'Amico, D; Farruggio, R; Miceli, D; Montesanti, A; Polito, L | 1 |
| Ho, SM; LaSpina, M; Lau, KM; Long, J | 1 |
1 review(s) available for fulvestrant and Prostatic Neoplasms
| Article | Year |
|---|---|
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Male; Neoplasms; Prostatic Neoplasms; Raloxifene Hydrochloride; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Signal Transduction; Treatment Outcome | 2008 |
1 trial(s) available for fulvestrant and Prostatic Neoplasms
| Article | Year |
|---|---|
Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Castration; Disease Progression; Dose-Response Relationship, Drug; Estradiol; Fulvestrant; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms; Receptors, Estrogen; Treatment Outcome | 2008 |
26 other study(ies) available for fulvestrant and Prostatic Neoplasms
| Article | Year |
|---|---|
9,11-Secosterols with antiproliferative activity from the gorgonian Eunicella cavolini.
Topics: Adenocarcinoma; Animals; Anthozoa; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Estrogens; Female; Humans; Male; Molecular Structure; Prostatic Neoplasms; Sterols | 2009 |
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
Topics: Antineoplastic Agents; Biomimetics; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Screening Assays, Antitumor; Female; Humans; Magnetic Resonance Spectroscopy; Male; Models, Chemical; Ovarian Neoplasms; Prostatic Neoplasms; Pterocarpans; Receptors, Estrogen; Stereoisomerism | 2011 |
Fulvestrant plus LHRH analogues in male with synchronous breast and prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Estradiol; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Letrozole; Male; Neoplasms, Multiple Primary; Nitriles; Prostatic Neoplasms; Tamoxifen; Triazoles | 2017 |
Androgens and estrogens stimulate ribosome biogenesis in prostate and breast cancer cells in receptor dependent manner.
Topics: Androgen Antagonists; Androgens; Anilides; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Male; MCF-7 Cells; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Receptors, Estrogen; Ribosomes; RNA, Neoplasm; RNA, Ribosomal; Signal Transduction; Tosyl Compounds; Transcription, Genetic | 2013 |
Genistein versus ICI 182, 780: an ally or enemy in metastatic progression of prostate cancer.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Disease Progression; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Fulvestrant; Gene Expression Regulation, Neoplastic; Genistein; Humans; Male; Metallothionein; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Prostatic Neoplasms; RNA, Small Interfering; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells.
Topics: Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Curcumin; Estradiol; Estrogen Receptor beta; Estrogen Receptor Modulators; Fulvestrant; Genistein; Humans; Male; Prostatic Neoplasms; Raloxifene Hydrochloride; Tamoxifen | 2014 |
Hsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Estradiol; Estrogen Receptor Antagonists; Estrogen Receptor beta; Fulvestrant; HMGA Proteins; Humans; Male; MicroRNAs; Neoplasm Invasiveness; Prostatic Neoplasms; Up-Regulation | 2014 |
Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells.
Topics: Binding Sites; Cell Line; DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Fulvestrant; G1 Phase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mutagenesis, Site-Directed; Mutant Proteins; Prostatic Neoplasms; Protein Binding; S Phase; Transcriptional Activation; Transgenes | 2008 |
Experience with fulvestrant acetate in castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Castration; Combined Modality Therapy; Estradiol; Fulvestrant; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms | 2010 |
Do we really need new trials on fulvestrant in prostate cancer?
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Castration; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Estradiol; Fulvestrant; Humans; Injections, Intramuscular; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 2010 |
PSA decrease with fulvestrant acetate in a hormone-resistant metastatic prostate cancer patient.
Topics: Acetates; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Compassionate Use Trials; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drugs, Investigational; Estradiol; Fulvestrant; Humans; Injections, Intramuscular; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Retreatment | 2010 |
Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Male; Mass Spectrometry; Mice; Mice, SCID; Orchiectomy; Prostatic Neoplasms; Receptors, Estrogen; Testosterone; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Research resource: estrogen-driven prolactin-mediated gene-expression networks in hormone-induced prostatic intraepithelial neoplasia.
Topics: Animals; Bromocriptine; Calgranulin B; Cell Proliferation; Chemokine CXCL13; Epithelial Cells; Estradiol; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Interleukin-1beta; Male; Prolactin; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Rats; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Testosterone | 2010 |
Synergistic chemoprotective mechanisms of dietary phytoestrogens in a select combination against prostate cancer.
Topics: bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cyclin E; Diet; Down-Regulation; Drug Synergism; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Genistein; Humans; Male; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phytoestrogens; Prostatic Neoplasms; Quercetin; Signal Transduction; Up-Regulation | 2011 |
Estrogens promote invasion of prostate cancer cells in a paracrine manner through up-regulation of matrix metalloproteinase 2 in prostatic stromal cells.
Topics: Cell Line, Tumor; Culture Media, Conditioned; Estradiol; Fulvestrant; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Paracrine Communication; Prostate; Prostatic Neoplasms; Receptors, Estradiol; Stromal Cells; Time Factors; Transforming Growth Factor beta1 | 2011 |
Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERβ and KLF5.
Topics: Aged; Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; CREB-Binding Protein; Estradiol; Estrogen Receptor beta; Estrogens; Forkhead Box Protein O1; Forkhead Transcription Factors; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Kruppel-Like Transcription Factors; Male; Mice; Middle Aged; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Cell Division; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Fulvestrant; Genistein; Histone Deacetylases; Humans; Hydroxamic Acids; Isoflavones; Male; Phytoestrogens; Plant Preparations; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Steroid Hydroxylases; Time Factors; Transcription, Genetic; Tumor Cells, Cultured; Vitamin D; Vitamin D3 24-Hydroxylase | 2003 |
Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells.
Topics: Androgen Antagonists; Androgens; Anilides; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Fulvestrant; Genes, Reporter; Humans; Male; Nitriles; Oligonucleotides, Antisense; Prostatic Neoplasms; Receptors, Androgen; Response Elements; Tosyl Compounds | 2004 |
Conference report--cancer research 2004--top of the class March 27-March 31, 2004; Orlando, Florida.
Topics: Androgen Antagonists; Animals; Breast Neoplasms; Cell Differentiation; Cell Proliferation; DNA Repair; Estradiol; Female; Fulvestrant; Genetic Therapy; Humans; Male; Neoplasms; Prostatic Neoplasms; Replication Protein A; Stem Cells | 2004 |
Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells.
Topics: Androgen Receptor Antagonists; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Male; Mutation; Prostatic Neoplasms; Receptors, Androgen; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Transcriptional Activation | 2004 |
ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Estradiol; Estrogen Receptor beta; Fulvestrant; Gene Expression Regulation, Neoplastic; Growth Differentiation Factor 1; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-12; Interleukin-8; Male; NF-kappa B; Prostatic Neoplasms; Receptor Protein-Tyrosine Kinases | 2006 |
Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Topics: Androgens; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured | 2006 |
Crosstalk between EGFR and extranuclear steroid receptors.
Topics: Androgen Receptor Antagonists; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Male; Phosphorylation; Prostatic Neoplasms; Receptor Cross-Talk; Receptors, Androgen; Receptors, Steroid; Signal Transduction; src-Family Kinases; Tyrosine; Up-Regulation | 2006 |
Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Cell Division; Cell Line, Tumor; Dehydroepiandrosterone; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Fulvestrant; Gene Expression; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; RNA, Small Interfering; Testosterone; Tosyl Compounds | 2007 |
Sex steroids up-regulate E-cadherin expression in hormone-responsive LNCaP human prostate cancer cells.
Topics: Androgen Antagonists; Cadherins; Dihydrotestosterone; Estradiol; Estrogen Antagonists; Flutamide; Fulvestrant; Gonadal Steroid Hormones; Humans; Immunoblotting; Immunohistochemistry; Male; Prostatic Neoplasms | 1995 |
Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
Topics: Cell Culture Techniques; Cell Division; Cells, Cultured; Diethylstilbestrol; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens, Non-Steroidal; Fulvestrant; Humans; Male; Methylation; Oligonucleotides, Antisense; Prostate; Prostatic Neoplasms; Protein Biosynthesis; Proteins; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Tamoxifen; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2000 |